Biogen Idec   1Q Revenues: $2.1 billion (+51%) 1Q Earnings: $480 million (+12%) Comments: TECFIDERA, recently approved for MS patients in Europe, had revenues of $506 million, comprised of $460 million the U.S. and approximately $46 million outside the U.S. AVONEX revenues increased 2% to $761 million. TYSABRI revenues were up 41% to $441 million due to recording 100% its revenues following the acquisition of complete asset rights in 2Q13. RITUXAN and GAZYVA revenues from an unconsolidated joi...